Induction of follicular growth and production of a normal hormonal milieu in spite of using a constant low dose of luteinizing hormone in women with hypogonadotrophic hypogonadism.
This study was designed to examine ovarian performance, i.e. follicular growth, normal steroidogenesis and luteal phase function, following the administration of multiple increasing doses of human follicle stimulating hormone (FSH) with a constant low dose of luteinizing hormone (LH) in women with isolated hypogonadotrophic hypogonadism. Human menopausal gonadotrophin (HMG) was used in the first treatment cycle, starting with 150 IU of LH and 150 IU of FSH per day, for 7 days. The dose was increased daily with 75 IU of LH and 75 IU of FSH for another 7 days if no response was detected by serial ultrasound measurements and serum oestradiol determinations. In the second treatment cycle, a constant dose of 75 IU of LH (using HMG) was administered per day and up to 150 IU of FSH (using urofollitrophin) was supplemented. If no response was detected after 7 days of treatment, the dose of FSH was increased. For the final stage of ovulation induction, human chorionic gonadotrophin (HCG) was administered in the presence of at least one follicle > 17 mm in diameter but with no more than three follicles > 16 mm in diameter. To verify the adequacy of the luteal phase, a pharmacokinetic/pharmacodynamic study of beta-HCG, oestradiol and progesterone was performed following the second treatment cycle only. Ovarian stimulation using a constant dose of 75 IU of LH and increasing doses of FSH up to 225 IU, resulted in normal follicular growth and hormonal milieu. Both women showed normal luteal phase oestradiol and progesterone production and both women conceived following the second treatment cycle.
Shoham
Z
Z
Department of Obstetrics and Gynecology, Kaplan Hospital, Rehovot, Israel.
Howles
C M
CM
Zalel
Y
Y
Weissman
A
A
Insler
V
V
D006063:Chorionic Gonadotropin / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use; D018997:Chorionic Gonadotropin, beta Subunit, Human; D004958:Estradiol / Q000096:biosynthesis / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy* / Q000503:physiopathology; D008183:Luteal Phase / Q000502:physiology*; D007986:Luteinizing Hormone / Q000008:administration & dosage* / Q000627:therapeutic use; D008596:Menotropins / Q000627:therapeutic use; D006080:Ovarian Follicle / Q000502:physiology*; D010062:Ovulation Induction; D010446:Peptide Fragments / Q000097:blood; D011374:Progesterone / Q000096:biosynthesis / Q000097:blood; D011446:Prospective Studies; D013256:Steroids / Q000096:biosynthesis*
D006063:Chorionic Gonadotropin; D018997:Chorionic Gonadotropin, beta Subunit, Human; D010446:Peptide Fragments; D013256:Steroids; D011374:Progesterone; D004958:Estradiol; D008596:Menotropins; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone